Abstract | PURPOSE: PATIENTS AND METHODS: RESULTS: Grade 3 or 4 toxicities were neutropenia and esophagitis in 19% of the patients each, and gastrointestinal toxicity in 17% of the patients. Of the 55 patients evaluable for response, 23.64% achieved complete response (CR) and 40% partial response (PR) (overall response rate 63.64%). Progression-free survival curves showed 1- and 2-year values of 42% and 21%, respectively, and median time to progression 10.5 months. The 1- and 2- year disease-specific survival was 58% and 29%, and the median overall survival 15 months. CONCLUSION:
|
Authors | P Rusu, T E Ciuleanu, D Cernea, D Pelau, V Gaal, C Cebotaru, T Guttman, N Todor, N Ghilezan |
Journal | Journal of B.U.ON. : official journal of the Balkan Union of Oncology
(J BUON)
2007 Jan-Mar
Vol. 12
Issue 1
Pg. 33-9
ISSN: 1107-0625 [Print] Cyprus |
PMID | 17436399
(Publication Type: Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antineoplastic Agents, Phytogenic
- Radiation-Protective Agents
- Vinblastine
- Carboplatin
- Amifostine
- Cisplatin
- Vinorelbine
|
Topics |
- Aged
- Amifostine
(therapeutic use)
- Antineoplastic Agents, Phytogenic
(administration & dosage)
- Antineoplastic Combined Chemotherapy Protocols
(adverse effects, therapeutic use)
- Carboplatin
(administration & dosage)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, pathology, radiotherapy)
- Chemotherapy, Adjuvant
- Cisplatin
(administration & dosage)
- Disease-Free Survival
- Drug Administration Schedule
- Feasibility Studies
- Female
- Humans
- Kaplan-Meier Estimate
- Lung Neoplasms
(drug therapy, radiotherapy)
- Male
- Middle Aged
- Neoplasm Invasiveness
- Neoplasm Staging
- Patient Compliance
- Radiation-Protective Agents
(therapeutic use)
- Radiotherapy, Adjuvant
- Time Factors
- Treatment Outcome
- Vinblastine
(administration & dosage, analogs & derivatives)
- Vinorelbine
|